A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Single Ascending Doses in Healthy Male and/or Female Subjects.

Trial Profile

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Single Ascending Doses in Healthy Male and/or Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2015

At a glance

  • Drugs AZD 5069 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 22 Jan 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top